DOI: 10.37421/2155-6113.2024.15.1002
DOI: 10.37421/2155-6113.2024.15.1003
Nucleoside reverse transcriptase inhibitors (NRTIs) are cornerstone antiretroviral drugs used in the treatment of HIV/AIDS. The advent of novel NRTIs has expanded therapeutic options, offering improved efficacy and safety profiles. This article explores the pharmacokinetics and pharmacodynamics of these novel NRTIs, emphasizing their absorption, distribution, metabolism and excretion (ADME) properties, as well as their mechanisms of action, resistance profiles and clinical implications.
DOI: 10.37421/2155-6113.2024.15.1004
Implementing Pre-Exposure Prophylaxis (PrEP) programs presents both challenges and opportunities in public health. Challenges include access barriers, stigma, adherence issues and cost. However, effective implementation offers significant opportunities to reduce HIV transmission rates, improve health equity and empower at-risk populations through education and support. This abstract explores these dynamics, highlighting the critical factors influencing successful PrEP program implementation.
DOI: 10.37421/2155-6113.2024.15.1005
The advent of long-acting antiretroviral therapies (LA-ARTs) has revolutionized HIV/AIDS management by addressing adherence challenges associated with daily medication regimens. LA-ARTs offer sustained drug levels, reducing dosing frequency to weekly or monthly intervals. This review explores the clinical implications and applications of LA-ARTs in HIV/AIDS care, emphasizing their impact on treatment adherence, viral suppression and quality of life. Key studies demonstrate comparable efficacy to daily regimens with potential benefits in resource-limited settings and among marginalized populations. Challenges such as safety profiles, patient acceptance and healthcare infrastructure requirements are also discussed. As LA-ARTs continue to evolve, their integration into global HIV/AIDS treatment strategies holds promise for improving long-term outcomes and reducing transmission rates.
DOI: 10.37421/2155-6113.2024.15.1006
DOI: 10.37421/2155-6113.2024.15.1007
DOI: 10.37421/2155-6113.2024.15.1008
DOI: 10.37421/2155-6113.2024.15.1009
DOI: 10.37421/2155-6113.2024.15.1010
DOI: 10.37421/2155-6113.2024.15.1001
Journal of AIDS & Clinical Research received 5061 citations as per Google Scholar report